White Paper Proposes 'Therapeutic Cloning' for Cures

- The scientific name for therapeutic cloning is Somatic Cell Nuclear Transfer (SCNT). This technique involves transferring the nucleus from a patient's body cell, like a skin cell, into a donor egg cell that has had its own nucleus removed. - A key goal of therapeutic cloning is to create patient-specific embryonic stem cells. Because these cells would be a 100% genetic match to the patient, they would not be rejected by the immune system, a major advantage over traditional organ and cell transplants. - The process is distinct from reproductive cloning, which aims to create a whole organism. In therapeutic cloning, the cloned embryo is only grown for a few days in a lab to the blastocyst stage (about 100 cells) to harvest stem cells; it is not implanted into a surrogate mother. - The first mammal to be successfully cloned from an adult cell using SCNT was Dolly the sheep, born in 1996. This event marked a significant milestone, demonstrating that the genetic material from a mature cell could be reprogrammed to create a new organism. - Major ethical debates surround therapeutic cloning, primarily because it involves the creation and subsequent destruction of a human embryo to harvest stem cells. This raises moral questions about the status of the embryo and the potential for the technology to be misused. - One of the biggest technical hurdles for human therapeutic cloning is the low availability of human eggs for research, as donation is an invasive procedure. Scientists estimate that hundreds of oocytes might be needed to create a single patient-specific stem cell line. - An alternative to therapeutic cloning that bypasses some ethical concerns is the use of induced pluripotent stem cells (iPSCs). This technology involves reprogramming adult cells (like skin cells) back into a stem-cell-like state without creating an embryo. - Proponents of therapeutic cloning argue it holds potential for treating a wide range of conditions, including neurodegenerative diseases like Parkinson's and diabetes, by replacing damaged cells. Clonell's white paper specifically targets "Cellular Senescence," the aging of cells, as the common factor behind the 34 diseases it aims to cure.